Colchicine Use After an Acute Coronary Syndrome

Findings of two randomized trials support long-term secondary prevention use but raise questions about short-term use at time of reperfusion.

Inflammation is a key driver of coronary artery disease, and anti-inflammatory medications like colchicine may provide an incremental therapeutic benefit. In the LoDoCo2 trial (actrn12614000093684), colchicine reduced the risk for cardiovascular events at ≥6 months after an acute coronary syndrome (ACS; NEJM JW Cardiol Oct 2020 and N Engl J Med 2020; 383:1838). However, questions remain about the timing of treatment following ACS. Two recent studies provide further data.

The first study, a secondary analysis of the randomized, placebo-controlled LoDoCo2 trial, assessed the benefit of 0.5 mg of colchicine once daily in 5522 patients with chronic coronary artery disease stratified by prior ACS status: no prior, recent (6–24 months), remote (2–…

Reviewing Author

Fatima Rodriguez, MD, MPH, FACC, FAHA

Disclosures

Consultant/Advisory BoardNovoNordisk; HealthPals; Novartis; Amgen

EquityHealthPals; Carta

Grant/Research SupportNational Institutes of Health/National Heart, Lung, and Blood Institute; American Heart Association–Robert Wood Johnson Foundation

Editorial BoardsCardiology and Therapy